Bisindolylmaleimide VIII is a selective PKC (protein kinase C) inhibitor, with observed binding activity to dystrophia myotonica protein kinase (DMPK). Bisindolylmaleimide VIII is suggested as being slightly more specific for PKC α over PKC β, PKC γ, and PKC ε isozymes (IC50 = 53, 195, 213, and 275 respectively). The compound has been shown to improve DR5-mediated apoptosis through the MKK4/JNK/p38 kinase. When bisindolylmaleimide VIII is combined with TRA-8 it can activate c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase. Studies have shown that bisindolylmaleimide VIII enhance Fas-mediated apoptosis in both human astrocytoma 1321N1 cells and in Molt-4T cells.
1. Zhou, T., et al. 1999. Nat. Med. 5: 42-48. PMID: 9883838
2. Ohtsuka, T. and Zhou, T. 2002. J. Biol. Chem. 277: 29294-29303. PMID: 12034736
3. Lautrette, C., et al. 2006. Apoptosis. 11: 1195-1204. PMID: 16699962
4. Elkins, J.M., et al. 2009. Protein Sci. 18: 782-791. PMID: 19309729
See how others have used Bisindolylmaleimide VIII. Click on the entry to view the PubMed entry .
PMID: # 25355318 Wang, Y. et al. 2014. The Journal of biological chemistry. 289: 35795-805.
PMID: # 19309729 Elkins, JM. et al. 2009. Protein Sci. 18: 782-791.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.